» Articles » PMID: 37062830

Identification of Mitochondrial Respiratory Chain Signature for Predicting Prognosis and Immunotherapy Response in Stomach Adenocarcinoma

Overview
Journal Cancer Cell Int
Publisher Biomed Central
Date 2023 Apr 16
PMID 37062830
Authors
Affiliations
Soon will be listed here.
Abstract

Stomach adenocarcinoma (STAD) is the third leading cause of cancer-related deaths and the fifth most prevalent malignancy worldwide. Mitochondrial respiratory chain complexes play a crucial role in STAD pathogenesis. However, how mitochondrial respiratory chain complex genes (MRCCGs) affect the prognosis and tumor microenvironment in STAD remains unclear. In this study, we systematically analyzed genetic alterations and copy number variations of different expression densities of MRCCGs, based on 806 samples from two independent STAD cohorts. Then we employed the unsupervised clustering method to classify the samples into three expression patterns based on the prognostic MRCCG expressions, and found that they were involved in different biological pathways and correlated with the clinicopathological characteristics, immune cell infiltration, and prognosis of STAD. Subsequently, we conducted a univariate Cox regression analysis to identify the prognostic value of 1175 subtype-related differentially expressed genes (DEGs) and screened out 555 prognostic-related genes. Principal component analysis was performed and developed the MG score system to quantify MRCCG patterns of STAD. The prognostic significance of MG Score was validated in three cohorts. The low MG score group, characterized by increased microsatellite instability-high (MSI-H), tumor mutation burden (TMB), PD-L1 expression, had a better prognosis. Interestingly, we demonstrated MRCCG patterns score could predict the sensitivity to ferroptosis inducing therapy. Our comprehensive analysis of MRCCGs in STAD demonstrated their potential roles in the tumor-immune-stromal microenvironment, clinicopathological features, and prognosis. Our findings highlight that MRCCGs may provide a new understanding of immunotherapy strategies for gastric cancer and provide a new perspective on the development of personalized immune therapeutic strategies for patients with STAD.

Citing Articles

Construction of molecular subtype and prognostic model for gastric cancer based on nucleus-encoded mitochondrial genes.

Wang X, Li S, Shen Y, Cao L, Lu Y, Cao J Sci Rep. 2024; 14(1):28491.

PMID: 39557952 PMC: 11574080. DOI: 10.1038/s41598-024-78729-0.

References
1.
Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

2.
Kang J, Lee S, Lim D, Park K, Oh S, Kwon H . Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012; 30(13):1513-8. DOI: 10.1200/JCO.2011.39.4585. View

3.
Ellinger J, Gromes A, Poss M, Bruggemann M, Schmidt D, Ellinger N . Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma. Oncotarget. 2016; 7(52):86490-86499. PMC: 5349929. DOI: 10.18632/oncotarget.13275. View

4.
Smyth E, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z . Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017; 3(9):1197-1203. PMC: 5824280. DOI: 10.1001/jamaoncol.2016.6762. View

5.
Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View